81946-31-8 Usage
Uses
Used in Pharmaceutical Industry:
3-Aminoquinolin-4(1H)-one is used as a potential antimalarial agent for its ability to inhibit the growth of Plasmodium falciparum, the parasite that causes malaria. Its effectiveness in combating this disease makes it a candidate for further research and development to create new treatments for malaria.
Additionally, 3-Aminoquinolin-4(1H)-one is used as an anticancer agent, as it has shown the ability to induce cell death in various cancer cell lines. This activity suggests its potential in developing new therapeutics for cancer treatment, warranting further exploration into its mechanisms of action and possible drug formulations.
Check Digit Verification of cas no
The CAS Registry Mumber 81946-31-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,1,9,4 and 6 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 81946-31:
(7*8)+(6*1)+(5*9)+(4*4)+(3*6)+(2*3)+(1*1)=148
148 % 10 = 8
So 81946-31-8 is a valid CAS Registry Number.
81946-31-8Relevant articles and documents
Discovery of N -(2,4-Di- tert -butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a potent and orally bioavailable CFTR potentiator
Hadida, Sabine,Van Goor, Fredrick,Zhou, Jinglan,Arumugam, Vijayalaksmi,McCartney, Jason,Hazlewood, Anna,Decker, Caroline,Negulescu, Paul,Grootenhuis, Peter D. J.
, p. 9776 - 9795 (2015/01/16)
Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screening in NIH-3T3 cells expressing the F508del-CFTR mutation. Extensive medicinal chemistry and iterative structure-activity relationship (SAR) studies to evaluate potency, selectivity, and pharmacokinetic properties resulted in the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for the treatment of CF patients 6 years of age and older carrying the G551D mutation.
